Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 13871
Sealed predictions
- GOLGA5 in dopamine neurons, braak+0.26 (p 0.493) → +0.53 (p 0.145)receipt 13878
Swarm cases
receipt 13878: GOLGA5 in dopamine neurons, braak
- power
- full sample +0.43 (p 0.074, n 18), 95% CI -0.04 to +0.75. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.30 (p 0.225, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.29 (p 0.243, n 18). could be the mix.
- skeptic
- leave-one-out range +0.36 to +0.60, sign flips 0; without severely affected donors +0.43 (p 0.074, n 18). robust.
- cell type
- strongest in astrocytes: -0.78 (p 1.6e-4, n 18) vs +0.43 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GOLGA5 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GOLGA5 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.18 p 0.534 (needs p < 1.7e-4)
Receipts
loading the receipts